Cytokines as immunomodulators in tuberculosis therapy

Recent Patents on Anti-Infective Drug Discovery

Volumn 3, Issue 3, 2008, Pages 168-176

  Rivero Lezcano, Octavio M ^a  

^a HOSPITAL DE LEÓN   (Spain)

Author keywords

Chemokines; Cytokines; M. tuberculosis; Monocytes macrophages; Neutrophils; T cells; XDR TB

Indexed keywords

ALPHA INTERFERON; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSERINE; CYTOKINE; ETHAMBUTOL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; ISONIAZID; KANAMYCIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROBIOTIC AGENT; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SALICYLIC ACID DERIVATIVE; THIOAMIDE; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

ADJUVANT THERAPY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CHRONIC INFLAMMATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; EPIDEMIC; GROWTH INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; LUNG TUBERCULOSIS; MACROPHAGE ACTIVATION; MULTIDRUG RESISTANCE; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL;

EID: 58149109209     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489108786242332     Document Type: Article

References (115)

1. Gutierrez MC, Brisse S, Brosch R, et al. Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis. PLoS Pathog 2005; 1: 55-61.
2. Mostowy S, Behr MA. The origin and evolution of Mycobacterium tuberculosis. Clin Chest Med 2005; 26: 207-216.
3. Daniel TM. The history of tuberculosis. Respir Med 2006; 100: 1862-1870.
4. Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med 2001; 345: 189-200.
5. Weiss RA, McMichael AJ. Social and environmental risk factors in the emergence of infectious diseases. Nat Med 2004; 10: S70-S76.
6. Anonymous. Global tuberculosis control: surveillance, planning, financing: WHO report 2008. Geneva, Switzerland: World Health Organization (WHO/HTM/TB/2008.393) 2008.
7. Young DB, Perkins MD, Duncan K, Barry III CE. Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest 2008; 118: 1255-1265.
8. De Souza MVN. Promising drugs against tuberculosis. Recent Patents Anti -Infect Drug Disc 2006; 1: 33-44.
9. Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13: 380-387.
10. Stead WW. Variation in vulnerability to tuberculosis in America today: Random, or legacies of different ancestral epidemics? Int J Tuberc Lung Dis 2001; 5: 807-814.
11. Gordon B, Cashman WM. Tuberculosis in workers after residence in a tuberculosis hospital. JAMA 1930; 94: 1643-1645.
12. Houk VN, Baker JH, Sorensen K, Kent DC. The epidemiology of tuberculosis infection in a closed environment. Arch Environ Health 1968; 16: 26-35.
13. Israel HL, Hetherington HW, Ord JG. A study of tuberculosis among students of nursing. JAMA 1941; 117: 839-844.
14. Bhatt K, Salgame P. Host innate immune response to Mycobacterium tuberculosis. J Clin Immunol 2007; 27: 347-362.
15. Co DO, Hogan LH, Kim SI, Sandor M. Mycobacterial granulomas: Keys to a long-lasting host-pathogen relationship. Clin Immunol 2004; 113: 130-136.
16. Schluger NW, Rom WN. The host immune response to tuberculosis. Am J Respir Crit Care Med 1998; 157: 679-691.
17. Ulrichs T, Kaufmann SH. New insights into the function of granulomas in human tuberculosis. J Pathol 2006; 208: 261-269.
18. Kaufmann SHE. Immune response to tuberculosis: Experimental animal models. Tuberculosis 2003; 83: 107-111.
19. Cardona PJ, Llatjós R, Gordillo S, et al. Towards a 'human-like' model of tuberculosis: intranasal inoculation of LPS induces Intragranulomatous lung necrosis in mice infected aerogenically with Mycobacterium tuberculosis. Scand J Immunol 2001; 53: 65-71.
20. Rook GAW, Steele J, Ainsworth M, Champion BR. Activation of macrophages to inhibit proliferation of Mycobacterium tuberculosis: comparison of the effects of recombinant gammainterferon on human monocytes and murine peritoneal macrophages. Immunology 1986; 59: 333-338.
21. Pozos TC, Ramakrishan L. New models for the study of Mycobacterium-host interactions. Curr Opin Immunol 2004; 16: 499-505.
22. Douvas GS, Looker DL, Vatter AE, Crowle AJ. Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infect Immun 1985; 50: 1-8.
23. Denis M. Killing of Mycobacterium tuberculosis within human monocytes: Activation by cytokines and calcitriol. Clin Exp Immunol 1991; 84: 200-206.
24. Warwick-Davies J, Dhillon J, O'Brien L, Andrew PW, Lowrie DB. Apparent killing of Mycobacterium tuberculosis by cytokine-activated human monocytes can be an artefact of a cytotoxic effect on the monocytes. Clin Exp Immunol 1994; 96: 214-217.
25. Byrd TF. Tumor necrosis factor α (TNF α) promotes growth of virulent Mycobacterium tuberculosis in human monocytes. J Clin Invest 1997; 99: 2518-2529.
26. Bonay M, Bouchonnet F, Pelicic V, et al. Effect of stimulation of human macrophages on intracellular survival of Mycobacterium bovis Bacillus Calmette-Guerin. Evaluation with a mycobacterial reporter strain. Am J Respir Crit Care Med 1999; 159: 1629-1637.
27. Silver RF, Li Q, Boom WH, Ellner JJ. Lymphocyte-dependent inhibition of growth of virulent Mycobacterium tuberculosis H37Rv within human monocytes: Requirement for CD4+ T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects. J Immunol 1998; 160: 2408-2417.
28. Bonecini-Almeida MG, Chitale S, Boutsikakis I, et al. Induction of in vitro human macrophage anti-Mycobacterium tuberculosis activity: requirement for IFN-γ and primed lymphocytes. J Immunol 1998; 160: 4490-4499.
29. Yoneda T, Ellner JJ. CD4+ T cell and natural killer cell-dependent killing of Mycobacterium tuberculosis by human monocytes. Am J Respir Crit Care Med 1998; 158: 395-403.
30. Brill KJ, Li Q, Larkin R, et al. Human natural killer cells mediate killing of intracellular Mycobacterium tuberculosis H37Rv via granule-independent mechanisms. Infect Immun 2001; 69: 1755-1765.
31. Thoma-Uszynski S, Stenger S, Takeuchi O, et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001; 291: 1544-1547.
32. 7-dependent process inducing bacterial death by phagosome-lysosome fusion. J Immunol 2001; 167: 3300-3307.
33. Garg SK, Volpe E, Palmieri G, et al. Sphingosine 1-phosphate induces antimicrobial activity both in vitro and in vivo. J Infect Dis 2004; 189: 2129-2138.
34. Boechat N, Bouchonnet F, Bonay M, et al. Culture at high density improves the ability of human macrophages to control mycobacterial growth. J Immunol 2001; 166: 6203-6211.
35. Robertson AK, Andrew PW. Interferon gamma fails to activate human monocyte-derived macrophages to kill or inhibit the replication of a non-pathogenic mycobacterial species. Microb Pathog 1991; 11: 283-288.
36. Reyes-Ruvalcaba D, Gonzalez-Cortes C, Rivero-Lezcano OM. Human phagocytes lack the ability to kill Mycobacterium gordonae, a non-pathogenic mycobacteria. Immunol Lett 2008; 116: 72-78.
37. Martineau AR, Newton SM, Wilkinson KA, et al. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest 2007; 117: 1988-1994.
38. Brown AE, Holzer TJ, Andersen BR. Capacity of human neutrophils to kill Mycobacterium tuberculosis. J Infect Dis 1987; 156: 985-989.
39. Jones GS, Amirault HJ, Andersen BR. Killing of Mycobacterium tuberculosis by neutrophils: A nonoxidative process. J Infect Dis 1990; 162: 700-704.
40. Kisich KO, Higgins M, Diamond G, Heifets L. Tumor necrosis factor alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils. Infect Immun 2002; 70: 4591-4599.
41. Majeed M, Perskvist N, Ernst JD, Orselius K, Stendahl O. Roles of calcium and annexins in phagocytosis and elimination of an attenuated strain of Mycobacterium tuberculosis in human neutrophils. Microb Pathog 1998; 24: 309-320.
42. Denis M. Human neutrophils, activated with cytokines or not, do not kill virulent Mycobacterium tuberculosis. J Infect Dis 1991; 163: 919-920.
43. Aston C, Rom WN, Talbot AT, Reibman J. Early inhibition of mycobacterial growth by human alveolar macrophages is not due to nitric oxide. Am J Respir Crit Care Med 1998; 157: 1943-1950.
44. Tan BH, Meinken C, Bastian M, et al. Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens. J Immunol 2006; 177: 1864-1871.
45. Stenger S, Hanson DA, Teitelbaum R, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998; 282: 121-125.
46. Stenger S, Rosat JP, Bloom BR, Krensky AM, Modlin RL. Granulysin: a lethal weapon of cytolytic T cells. Immunol Today 1999; 20: 390-394.
47. Dieli F, Troye-Blomberg M, Ivanyi J, et al. Granulysin-dependent killing of intracellular and extracellular Mycobacterium tuberculosis by Vγ9/Vδ2 T lymphocytes. J Infect Dis 2001; 184: 1082-1085.
48. Gansert JL, Kießler V, Engele M, et al. Human NKT cells express granulysin and exhibit antimycobacterial activity. J Immunol 2003; 170: 3154-3161.
49. Pirofski LA, Casadevall A. Immunomodulators as an antimicrobial tool. Curr Opin Microbiol 2006; 9: 489-495.
50. Masihi KN. Immunomodulators in infectious diseases: Panoply of possibilites. Int J Immunopharmacol 2000; 22: 1083-1091.
51. Labro MT. Interference of antibacterial agents with phagocyte functions: Immunomodulation or "immuno-fairy tales"? Clin Microbiol Rev 2000; 13: 615-650.
52. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-146.
53. Ottenhoff TH, Verreck FA, Hoeve MA, van de Vosse E. Control of human host immunity to mycobacteria. Tuberculosis 2005; 85: 53-64.
54. Ferraz JC, Melo FB, Albuquerque MF, Montenegro SM, Abath FG. Immune factors and immunoregulation in tuberculosis. Braz J Med Biol Res 2006; 39: 1387-1397.
55. Nathan CF, Remold HG, David JR. Characterization of a lymphocyte factor which alters macrophage functions. J Exp Med 1973; 137: 275-290.
56. Simon HB, Sheagren JN. Cellular immunity in vitro. I. Immunologically mediated enhancement of macrophage bactericidal capacity. J Exp Med 1971; 133: 1377-1389.
57. Fowles RE, Fajardo IM, Leibowitch JL, David JR. The enhancement of macrophage bacteriostasis by products of activated lymphocytes. J Exp Med 1973; 138: 952-964.
58. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-γ as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983; 158: 670-689.
59. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258-267.
60. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-γ: An overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75: 163-189.
61. Wallis RS. Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 2005; 41: 201-208.
62. Condos R, Raju B, Canova A, et al. Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. Infect Immun 2003; 71: 2058-2064.
63. Suárez-Méndez R, García-García I, Fernández-Olivera N, et al. Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: A pilot study. BMC Infect Dis 2004; 4: 44-51.
64. Koh WJ, Kwon OJ, Suh GY, et al. Six-month therapy with aerosolized interferon-γ for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci 2004; 19: 167-171.
65. Kawakami K. Promising immunotherapies with Th1-related cytokines against infectious diseases. J Infect Chemother 2003; 9: 201-209.
66. Park SK, Cho S, Lee IH, et al. Subcutaneously administered interferon-gamma for the treatment of multidrug-resistant pulmonary tuberculosis. Int J Infect Dis 2007; 11: 434-440.
67. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982-989.
68. National Heart LaBIN. Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs. ClinicalTrials.gov Identifier: NCT00201123 2005.
69. Bogdan C, Mattner J, Schleicher U. The role of type I interferons in non-viral infections. Immunol Rev 2004; 202: 33-48.
70. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8-32.
71. Giosuè S, Casarini M, Alemanno L, et al. Effects of aerosolized interferon-α in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1998; 158: 1156-1162.
72. Giosuè S, Casarini M, Ameglio F, et al. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytokine Netw 2000; 11: 99-104.
73. Palmero D, Eiguchi K, Rendo P, Castro Zorrilla L, Abbate E, González Montaner LJ. Phase II trial of recombinant interferon-α2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up. Int J Tuberc Lung Dis 1999; 3: 214-218.
74. Sabbatani S, Manfredi R, Marinacci G, Pavoni M, Cristoni L, Chiodo F. Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis. Scand J Infect Dis 2006; 38: 205-208.
75. Telesca C, Angelico M, Piccolo P, et al. Interferon-alpha treatment of hepatitis D induces tuberculosis exacerbation in an immigrant. J Infect 2007; 54: e223-e226.
76. Koung, N.B.A.B., Amvam, Z.P.H., Gauchet, J.Y.: WO05039614 (2005).
77. van Crevel R, Ottenhoff TH, van der Meer JW. Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev 2002; 15: 294-309.
78. Algood HM, Chan J, Flynn JL. Chemokines and tuberculosis. Cytokine Growth Factor Rev 2003; 14: 467-477.
79. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008; 214: 149-160.
80. Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 2003; 21 Suppl 2: S2/24-S2/34.
81. Denis M, Ghadirian E. Granulocyte-macrophage colony-stimulating factor restricts growth of Tubercle bacilli in human macrophages. Immunol Lett 1990; 24: 203-206.
82. Root RK, Dale DC. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: Comparisons and potential for use in the treatment of infections in nonneutropenic patients. J Infect Dis 1999; 179 Suppl 2: S342-S352.
83. Grabstein, K.H., Morrissey, P.J.: US5162111 (1992).
84. Pedral-Sampaio DB, Netto EM, Brites C, et al. Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. Braz J Infect Dis 2003; 7: 245-252.
85. Cooper AM, Solache A, Khader SA. Interleukin-12 and tuberculosis: an old story revisited. Curr Opin Immunol 2007; 19: 441-447.
86. Trinchieri, G., Lee, W.M.F., Koblish, H.: US20026375944 (2002).
87. Metzger, D.W., Arulanandam, B.P.: US5985264 (1999).
88. Alber, G., Carr, J.A., Mattner, F.A., Mulqueen, M.J., Palmer, K., Rogerson, J.A.L.: US5928636 (1999).
89. Kaplan, G., Oliver, S.J., Haslett, P.A.J.: WO000072836 (2000).
90. Fu LM, Fu-Liu CS. Thalidomide and tuberculosis. Int J Tuberc Lung Dis 2002; 6: 569-572.
91. Sung, Y.C., Lee, S.H., Ha, S.J., Song, M.K., Chang, J.: US20077253151 (2007).
92. Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol 2004; 172: 3983-3988.
93. Johnson BJ, Bekker LG, Rickman R, et al. RhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis 1997; 78: 195-203.
94. Johnson JL, Ssekasanvu E, Okwera A, et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168: 185-191.
95. Skvortsova LA, Pavlova MV, Vinogradova TI, Archakova LI. Combined therapy of pulmonary tuberculosis by using recombinant interleukins. Probl Tuberk Bolezn Legk 2003; 9-12.
96. Chu NH, Zhu LZ, Yie ZZ, et al. A controlled clinical study on the efficacy of recombinant human interleukin-2 in the treatment of pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 2003; 26: 548-551.
97. Lane, C.H., Kovacs, J.A., Fauci, A.S.: US20016190656 (2001).
98. Enssle, K., Kurrle, R., Lauffer, L., Seiler, F.: US20016210661 (2001).
99. Reed, S.G.: US5730976 (1998).
100. Alpdogan Ö, van den Brink MRM. IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol 2005; 26: 56-64.
101. Kibiki GS, Myers LC, Kalambo CF, et al. Bronchoalveolar neutrophils, interferon gamma-inducible protein 10 and interleukin-7 in AIDS-associated tuberculosis. Clin Exp Immunol 2007; 148: 254-259.
102. Alderson MR, Tough TW, Ziegler SF, Grabstein KH. Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J Exp Med 1991; 173: 923-930.
103. Grabstein, K.H., Alderson, M.: US5681557 (1997).
104. Schwertschlag US, Trepicchio WL, Dykstra KH, Keith JC, Turner KJ, Dorner AJ. Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia 1999; 13: 1307-1315.
105. Trepicchio, W.L., Bliss, J.L., O'toole, M., Dorner, A.J.: WO049937322 (2004).
106. Cruikshank WW, Kornfeld H, Center DM. Interleukin-16. J Leukoc Biol 2000; 67: 757-766.
107. Qin XJ, Shi HZ, Huang ZX, Kang LF, Mo WN, Wu C. Interleukin-16 in tuberculous and malignant pleural effusions. Eur Respir J 2005; 25: 605-611.
108. Center, D.M., Cruikshank, W.W., Kornfeld, H.: US20006159463 (2000).
109. Khader SA, Cooper AM. IL-23 and IL-17 in tuberculosis. Cytokine 2008; 41: 79-83.
110. Medlock, E., Yeh, R., Silbiger, S.M., Elliott, G.S., Nguyen, H.Q., Jing, S.: US20067094566 (2006).
111. Saukkonen JJ, Bazydlo B, Thomas M, Strieter RM, Keane J, Kornfeld H. β-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infect Immun 2002; 70: 1684-1693.
112. Dürr M, Peschel A. Chemokines meet defensins: The merging concepts of chemoattractants and antimicrobial peptides in host defense. Infect Immun 2002; 70: 6515-6517.
113. Haodong, LI., Ruben, S., Sutton, G.G.: WO031467 (1995).
114. Olsen, H.S., Haodong, LI., Adams, M.D., Gentz, S.H.L., Alderson, R., Yuling LI., Parmelee, D., White, J.R., Appelbaum, E.R., Salcedo, T.: WO01094557 (2001).
115. Goldsack L, Kirman JR. Half-truths and selective memory: Interferon gamma, CD4+ T cells and protective memory against tuberculosis. Tuberculosis 2007; 87: 465-473.